- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05199753
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
September 17, 2023 updated by: LaNova Australia Pty Limited
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: LaNova PM
- Phone Number: +8615901815211
- Email: alexyuan@lanovamed.com
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, NSW 2148
- Recruiting
- Blacktown Hospital
-
Contact:
- Site 02
-
-
Queensland
-
Birtinya, Queensland, Australia, QLD 4575
- Recruiting
- Sunshine Coast University Private Hospital
-
Contact:
- Site 07
-
South Brisbane, Queensland, Australia, QLD 4101
- Recruiting
- ICON Cancer Centre
-
Contact:
- Site 04
-
-
Victoria
-
Malvern, Victoria, Australia, VIC 3144
- Recruiting
- Cabrini Health Limited
-
Contact:
- Site 03
-
Melbourne, Victoria, Australia, VIC 3004
- Recruiting
- Alfred Hospital
-
Contact:
- Site 05
-
-
Western Australia
-
Nedlands, Western Australia, Australia, WA 6009
- Recruiting
- One Clinical Research Pty Ltd.
-
Contact:
- Site 01
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
- At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
- Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Key Exclusion Criteria:
- Any adverse event from prior anti-tumour therapy has not yet recovered to ≤grade 1 of CTCAE v5.0
- Uncontrolled tumour-related pain
- Known central nervous system (CNS)
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- Use of inhaled corticosteroids
- Known history of autoimmune disease
- Use of any live attenuated vaccines within 28 days
- Have severe cardiovascular disease
- Uncontrolled or severe illness
- History of immunodeficiency disease
- Active malignancies which are likely to require the treatment.
- Child-bearing potential female
- Have psychiatric illness or disorders
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LM-108 Dose Escalation
|
Administered intravenously
|
Experimental: LM-108 Dose Expansion
|
Administered intravenously
|
Experimental: LM-108 combination dose escalation
|
Administered intravenously
Administered intravenously
|
Experimental: LM-108 combination dose expansion
|
Administered intravenously
Administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events (AEs)
Time Frame: 126 weeks
|
126 weeks
|
Incidence of serious adverse event (SAE)
Time Frame: 126 weeks
|
126 weeks
|
Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.
Time Frame: 126 weeks
|
126 weeks
|
Incidence of dose-limiting toxicity (DLT)
Time Frame: 126 weeks
|
126 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of anti-drug antibodies to LM-108
Time Frame: 126 weeks
|
126 weeks
|
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Minimum Observed Concentration (Cmin) for LM-108
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Steady State Maximum Concentration (Cmax,ss)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Steady State Minimum Concentration (Cmin, ss)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Systemic Clearance at Steady State (CLss)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Accumulation Ratio (Rac)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Elimination Half-life (t 1/2)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Volume of Distribution at Steady-State (Vss)
Time Frame: 126 weeks
|
126 weeks
|
PK Parameter: Degree of Fluctuation (DF)
Time Frame: 126 weeks
|
126 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 16, 2022
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
December 15, 2021
First Submitted That Met QC Criteria
January 6, 2022
First Posted (Actual)
January 20, 2022
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 17, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LM108-01-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on LM-108
-
LaNova Medicines LimitedRecruitingAdvanced Solid TumorChina
-
LaNova Medicines LimitedTerminatedAdvanced Solid TumorUnited States
-
Kangbuk Samsung HospitalCompletedMyomaKorea, Republic of
-
LaNova Medicines Development Co., Ltd.Shanghai Zhongshan Hospital; First Affiliated Hospital of Zhejiang University; Sir Run Run Shaw Hospital and other collaboratorsTerminated
-
Dow Pharmaceutical SciencesCompleted
-
LaNova Medicines LimitedRecruiting
-
LaNova Medicines Zhejiang Co., Ltd.Active, not recruiting
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
Henan Cancer HospitalRecruitingNSCLC | Brain Metastases | Leptomeningeal MetastasisChina
-
SRI InternationalTaiho Pharmaceutical Co., Ltd.CompletedBreast CancerUnited States